Workshops at BioTrinity 2011
The workshops at BioTrinity 2011 will be more like roundtable discussions than seminars, and as organisers we demand that they are interactive. Participation at workshops is included in the conference registration fee, however as spaces are limited, pre-registered delegates are advised to sign up for workshops online and in advance via the online partnering system's Agenda Planner which is available to all registrants, to reserve their places. Workshops will be held over both days of the conference, 13 - 14th April, Level 1 of The Grandstand. You will be able to walk in to join workshops at the start of their sessions, but pre-registered participants will take precendent over those who walk in.
We are pleased to bring you workshops from Invest in Skane, James Cowper, Almac Group, Oxfordshire Biomedical Research Centre and Oxford University Medical Sciences, Eagle Genomics, HealthTIES and Roche Partnering with College Hill Life Sciences. There is a single track of workshops, complementing the single track of company presentations in the Conference Hall.
Full details of 2011 Workshops are listed below
Workshops Day 1: Wednesday, 13th April 2011
Level 1, The Grandstand
| 13.30 - 14.00 | Poised on the pinnacle of success… Managing before the equity comes in Host: Sue Staunton, James Cowper |
| Abstract | Many biotech and medical device companies are familiar with the frustration of having ground-breaking intellectual property but being unable to develop it whilst waiting for funding to come in. The workshop looks at ways in which this can be managed.
|
| 14.00 - 15.00 | Drug Discovery and Development at the Heart of Scandinavia Host: Lovisa Sunesson, Invest in Skåne |
| Abstract | Scania (Southern Sweden) as part Medicon Valley is a strategic location for drug discovery and development in Scandinavia. Thanks to an innovative research environment, the access to outstanding infrastructures and the unique patient registers, Scania offers the highest quality throughout drug development to commercialisation. Five companies will present their technology and services focusing on: structural biology and drug design (SARomics), formulation (Galenica), physical pharmacy (CR Competence) and phase I to IV trials (Commitum, TFS).
|
| 15.00 | Refreshments, Networking and Exhibition Viewing, The Grandstand, Ground Floor
|
| 15.30 - 16.30 | RapiddTM - A Case Study on Accelerated Integrated Drug Development Hosted by Helen McKeever, Almac |
| Abstract | A short presentation on the challenges of conducting integrated early drug development programmes, taking into consideration efficient cost-effective planning, API production, preformulation development, preclinical safety & toxicity testing and regulatory support. To be followed by an interactive exercise to design a CTA/IND-enabling programme.
|
| 16.30 - 17.30 | Introducing Innovative Genomics Technologies into the NHS; Barriers and Opportunities Host: Clive Savory, University of Oxford |
| Abstract | The introduction of innovative molecular diagnostic technologies in the NHS presents many challenges for private sector providers. Emerging technologies may need specific adaptation for use in either research or diagnostic settings. An understanding of the pathway to the NHS, clinician and laboratory users and routes to commissioning can be particularly challenging. The Oxford Biomedical Research Centre has extensive experience of translating novel molecular diagnostics tests and genomics technologies into routine clinical practice – and collaborating with industry to achieve this. Case studies will be provided, demonstrating how potential barriers to translation can be overcome, and opportunities for future partnering in these sectors highlighted.
|
Workshops on Day 2: Thursday 14th April
Level 1, The Grandstand
| 11.00 – 11.30 | Computing in the Age of the $1000 Genome Hosted by William Spooner, Eagle Genomics |
| Abstract | This workshop will examine the opportunities and challenges presented by cheap, abundant DNA sequencing. Will cloud computing, genome content management or outsourcing help span the widening gulf between data generation cost and data analysis cost? Such questions will be examined at the workshop, facilitated by Eagle's recent bioinformatics community survey. The ensuing debate is likely to engage all stakeholders in computational biology over the coming decade. See the survey at www.eaglegenomics.com/survey
|
| 11.30 – 12.00 | 'Healthy ageing' for companies; the importance of clusters Hosted by Roel Kamerling, HealthTIES |
| Abstract | Innovation is a global game nowadays. Innovative companies tend to foster on a few innovative hot spots around the world. The availability of a highly educated workforce, funding and specialized service providers create a fur tile ground for success. Will this still be true in the next decades when an ever increasing free movement of people, money and ideas seem to diminish the local success factor. Where do you need to be in the next decade to maximize your chances for success? The HealthTIES cooperation of Oxford, Zurich, Medical Delta, Barcelona and Debrecen intends to find answers to these questions. The workshop is meant to share first findings with the participants and to offer practical guidelines to participants who search for innovation hot spots. |
| 12.00 – 12.30 | Provide large pharma with an offer they can't refuse Hosted by Margaret Beer, Senior Director and Head, Licensing and External Research, Merck Sharpe & Dohme; Barry Porter, CEO, Union Life Sciences |
| Abstract | To follow
|
| 12.30 | Lunch, Networking and Exhibition Viewing, The Grandstand, Ground Floor
|
| 13.30 – 14.30 | Building reputation to drive corporate strategy: A masterclass in biotech communications Hosted and sponsored by Roche Partnering, Peter Sandbach, Head of Communications and Sue Charles, College Hill Life Sciences |
| Abstract | This interactive master class in biotechnology communications will bust the myth that scientists, businesses and investors make decisions based solely on data. Veteran communicators from pharma and biotech will lead an interactive session to demonstrate how perceptions create reputations and brands. In particular the workshop will cover branding and messaging. Valuable tips on how best to build a brand with trust and confidence, as well as using emotion to engage and persuade stakeholders will be provided.
|
| 14.30 – 15.30 | European Diagnostic Cluster Alliance Hosts: Bruce Savage, Representative, OBN; Eddie Ezzarani, International Relations WAL-Dx, BioWin; Franck Molina, Director Sysdiag, Eurobiomed-Euromediag; Michel Kaczorek, Projects Director, Eurobiomed |
| Abstract | The new European Diagnostic Clusters Alliance (EDCA) involving UK (OBN/Nexxus), France (Eurobiomed), Belgium (BioWin), Poland (Krakow), Sweden (Upssala Bio), Germany (ZMDB), and Spain (BioCat) promotes medical diagnostic companies and helps them tap into a multi-billion-pound emerging global market. The workshop will highlight how IVD players can form partnerships across Europe, attract new sources of funding from the EU (e.g. FP7), and access to non-EU markets. The association also wishes to stimulate joint ventures between pharma, academia and SMEs.
|
| 15.30 – 16.00 | Innovation Poster Winners Oral Presentations The CD8 Transcriptome predicts prognosis in Autoimmune Disease: Paul Lyons, Senior Research Associate, Cambridge Institute for Medical Research and Department of Medicine; Novel Dual Inhibators of FLT3 and Aurora Kinases: Spiros Linardopoulos, Team Leader, Institute of Cancer Research; Senectus Therapeutics: targeting cellular senescence for anti-cancer therapies: Nicol Keith, Professor of Molecular Oncology, CRUK Beatson Laboratories, University of Glasgow |
Below are examples of 2010 workshop details.
Workshops Day 1: Tuesday, 13th April 2010
| Berkshire Stand, Fred Winter Suite, 2nd Floor | |
| 12:00-12:30 | A Strategy for Skills, Salaries and Shortages Hosts: Ena Vieira, Commercial Manager, SRG Recruitment The UK leads Europe in the industrial exploitation of biotechnology. During the last decade there has been a rapid and continued growth in the number of specialist biotechnology R&D based companies with over 40,000 people currently employed within the industry, most of whom are placed in highly skilled roles. However, will future growth be jeopardised by "brain drain"? “Britain will face a new brain drain of scientific talent to the US if the next government cuts the research budget to contain the £178 billion national debt, according to a group of America's most senior and respected scientists.” (The Times 23rd February 2010.) Utilising recent research, the Biotrinitiy workshop on "A Strategy for Skills, Salaries and Shortages" will outline the current demand and salary levels within the biotech sector for scientitic skills and, through an interactive session in which attendees can participate, will prioirtise the skills needed by the Biotech industry in the future and produce a "skills statement" for the sector. |
| 13:30-14:00 | Checking it out....common stumbling blocks during due diligence Host: Sue Staunton, Partner, James Cowper Whether you are looking to exit or bring in investment or debt into your life science based business, your company will probably find itself the subject of a due diligence process. If you are a growing business you may be seeking to make an investment or acquisition in another company and, therefore, will be looking to execute such a process. During this workshop, business advisers and accountants, James Cowper, will discuss the process of financial due diligence, highlighting what those carrying out due diligence are looking for, identifying common stumbling blocks, and suggesting ways to prepare for such a process so that you can portray your business in its best light. James Cowper routinely carry out due diligence assignments on behalf of clients ranging from Banks and investors to those looking to acquire other businesses. With their understanding of the life science sector they recognise what is likely to be important to their client and tailor their approach accordingly" |
| 14:00-15:00 | Why are solid forms still causing headaches? Hosts: Linda McCausland, Head of Physical Sciences, Almac Group Drug Development Services While many in the pharmaceutical industry believe that solid state chemistry is well established and major dilemmas are a thing of the past, our experience shows that this is not the case. Almac has the privilege to work on many diverse projects for pharma and biotech companies. Using case studies we will reflect on issues such as; rescuing poorly bioavailable drugs, generating valuable intellectual property, developing the ‘wrong’ form, unwelcome guests at the 11th hour. |
| 15:30-16:30 | Patents: What’s The Point? Hosts: Graham Lock, Partner; Mark Sweetingburgh, Patent Attorney, Fry Heath Spence The workshop will cover the advantages and disadvantages of the patent system, examples of when patent protection is not appropriate, a reminder of the requirements for obtaining patent protection with a particular focus on what can be protected in the field of biotechnology, and the best strategies to employ when considering patent protection in this area. Questions will be welcomed throughout the workshop and it is hoped that an interesting and informative discussion will ensue! |
| 16:30-17:00 | Introducing the OBN Clinical Trials Insurance Scheme Hosts: Steve Ilott, Partner, FOCUS, Paul Monaco, Commercial Insurance Manager, FOCUS, Rob Evans, Business Development Director, FOCUS and Colby Walker, Senior Life Science Underwriter, Chubb Insurance Europe This workshop will explain the special OBN Clinical Trials Insurance scheme for members of OBN. Explanation of the features of this scheme which will be of significant benefit to OBN members who either have this protection or wish to enhance their protection levels or companies who may be embarking on a Clinical Trials programme. |
Workshops on Day 2: Wednesday 14th April
| Berkshire Stand, Fred Winter Suite, 2nd Floor | |
| 12:00-12:30 | Current legal issues for life sciences companies Hosts: Jim Kinnier Wilson, Partner Head of Life Sciences; Chris Shelley, Partner; Patrick Baddeley, Partner, Manches LLP The workshop will examine current legal issues facing life sciences companies, such as the protection and exploitation of intellectual property, commercial agreements, company structures and funding for growth. The team will address how to use these to your best advantage. |
| 13:30-14:00 | Unlocking European R&D Funding. Opportunities for Pharma, Health and Biotechnology SMEs Host: Graham Hughes Thought about looking to Europe to secure R&D funding? This workshop will provide an open and honest overview of the European Framework Programme, demystifying some of the common misconceptions and looking at the pros and cons from the viewpoint of the SME. It will provide some practical advice about the application process, identify resources for help and support and touch upon some other funding schemes suitable for the SME community. Open to complete beginners as well as old hands. |
| 14:30-15:00 | Planning for Recovery – the Remuneration Issues Hosts: Rod Cook, Partner, Biotech Personnel; Andy Christie, Senior Consultant, Hewitt New Bridge Street Last year saw an unprecedented number of pay freezes being applied to all sectors in the UK and the continued economic uncertainty may mean that the picture on pay reviews could take longer to emerge than before. Now we are out of recession, if only just, how will companies react at their next pay review and how difficult will it be to continue to apply restraint against predictions that we will see a sharp rise in the RPI over the coming months? Andy & Rod will discuss how companies can plan to meet the remuneration issues they will face and what steps may be available to respond to the market with both salaries and benefits. |
| 15:30-16:30 | Vacancy |
| 16:45 | Meeting close |
Below are examples of 2009 workshop details.
2009 Workshops:
| Thursday 2nd April 2009 - Workshops - Landmark Suite, Upper Floor | |
| 11:00-12:00 | Purchasing from distressed sellers - tips and traps Workshop Details - Host: Patrick Baddeley, Corporate Finance Partner, Manches LLP |
| 12:00-12:30 | Spinning out the Oxford Way Workshop Details - Host: Sue Staunton, Partner, James Cowper and Linda Naylor, Head of Tech Transfer, Isis Innovation |
| 13.30-14.30 | Developments in EU Rare Disease Policy and implications for pipeline products Workshop Details - Host: Wills Hughes-Wilson, Senior Director, Genzyme |
| 14:30-15:00 | How to streamline IP strategy for dual US and European patent protection and enforcement Workshop Details - Host: Dr Tony Maschio, Partner & Dr Kathleen Williams, Partner & Dr. Candi Soames, PartnerEdwards Angell Palmer & Dodge Innovations LLP |
| 15.30-16.00 | Patents in the credit crunch: keeping costs down Workshop Details - Host: Rebecca Tollervey, Mewburn Ellis LLP |
| 16:00-16:30 | Evaluating Innovative Technologies: Reimbursement and Market Access Planning Workshop Details - Host: Adam Barak, VP, Boston Healthcare Associates, Inc |
| Friday 3rd April 2009 - Workshops | |
| 10:00-10:30 | When it hits the fan: How to retain and motivate key employees when finances are restricted Workshop Details - Host: Rod Cook, Biotech Personnel |
| 11:30-12:00 | Accelerated Process Integrated Drug Development Workshop Details - Host: Denis Geffroy, Almac |
| 14:00-14:30 | How to Access Wellcome Trust Translational Funding Workshop Details - Host: Richard Seabrook and Nick Dunster, The Wellcome Trust |
| 14:30-15:00 | The IMI opportunities for biotechnology companies Workshop Details - Host: Jackie Hunter, GSK |
Workshop registration
You can book into workshops using the online partnering system, accessible once you register. This will help us to allocate your partnering meetings around the workshops you wish to attend, helping you access everything you wish.
Workshop Details
Purchasing from distressed sellers - tips and traps
One man's misfortune is another man's fortune. While the current economic downturn may not be good news for some companies, it will also present opportunities for others with cash to spare and an eye for a bargain. However, if you are in a position to purchase assets from a company in distress, you will need to understand that the process is different from a normal transaction. You need to set your approach and expectations accordingly. In this workshop experts from our corporate, employment and intellectual property departments will take you through some of the tips and traps inherent in purchasing financially distressed businesses including managing transfer of risk, ownership of IP, supplier's retention of title claims, retaining leased equipment and use of premises and employment liabilities.
Spinning out the Oxford Way
Sue Staunton, Partner, James Cowper and Linda Naylor, Head of Tech Transfer, Isis Innovation
Isis Innovation and James Cowper will discuss the methodologies for spinning out life science based businesses used by the University of Oxfords technology transfer company
Developments in EU Rare Disease Policy and implications for pipeline products
Host: Wills Hughes-Wilson, Senior Director, Genzyme
In the 10 years since the adoption of the EUs Orphan Regulation the EU legislative framework has further evolved to take account of new technologies, including cell- and gene-therapies. Recent proposals for the creation of National Plans and further cooperation between Member States in sharing information to facilitate market access are also currently under discussion. Genzyme played a leading role in the creation of the EUs orphan system and has continued to do so. The environment regulating pipeline products has become increasingly complex to navigate, but there is a pathway through.
How to streamline IP strategy for dual US and European patent protection and enforcement
Dr Tony Maschio & Dr Kathleen Williams & Dr. Candi Soames, Edwards Angell Palmer & Dodge Innovations LLP
For the vast majority of biopharmaceutical companies, the US is the most important market in terms of potential sales, collaborations and sources of investment. Despite this, for most European companies, IP strategy is designed around a European model and does not take into consideration the particular requirements of US law. In this workshop, European patent attorneys Dr. Candi Soames and Dr. Tony Maschio, together with registered US patent attorney Dr. Kathleen Williams, will explain how to optimise European strategy to obtain the best advantage both in Europe and the US.
Patents in the credit crunch: keeping costs down
Rebecca Tollervey & Simon Kiddle, Mewburn Ellis LLP
Working within an IP budget is always a challenge. There is an ongoing need to reduce costs while ensuring that valuable intellectual property is protected and the right expert advice is obtained. We will be discussing how costs can be kept down by careful filing strategies, and identifying points in the life of a patent where savings can be made.
Evaluating Innovative Technologies: Reimbursement and Market Access Planning
Adam Barak, VP, Boston Healthcare Associates, Inc
For companies developing innovative technologies, it is essential to prepare to achieve payer endorsement as well as to secure the necessary licences which will enable them to launch their products in a given territory. Payers in all countries have been introducing various means of managing healthcare expenditures, and it therefore behoves a company hoping to secure payment for its technology to know what the payers expectations are in order for the technology to achieve reimbursement and enable optimal market access.
Similarly, without knowing what the payers expectations are, it is very difficult to derive what an optimal in-market price should be or what the international price range should be for the technology and therefore what its value is in terms of sales expectations or its acquisition potential.
We will explain the steps and activities needed to determine how a company can evaluate what a technologys price should be, how it can achieve reimbursement and how the value of the technology can be assessed and appraised.
When it hits the fan: How to retain and motivate key employees when finances are restricted
Rod Cook, Partner, Biotech Personnel
There is clear evidence that redundancy programmes do not always produce the savings expected. Rod will draw on his experience of assisting clients with budget restrictions to discuss ways of either avoiding redundancies or minimising the impact. He will refer to data from the most comprehensive remuneration survey of the UK biotech industry.
Accelerated Process Integrated Drug Development
Denis Geffroy, Almac
A new approach to early clinical development using our specialist technologies where appropriate e.g. Biocatalysis, Peptides, Solid State Services. A complete set of solutions aimed at accelerating entry into clinical development; saving on average 1 year from the early clinical development timelines. The RAPIDDTM package includes an integrated set of services (API, Drug Product, Pre-clinical tox and safety studies) speeding up entry into Phase I clinical trials (First in Man).
How to Access Wellcome Trust Translational Funding
Richard Seabrook and Nick Dunster, The Wellcome Trust
Technology Transfer at the Wellcome Trust is a committed funder of translational research. Bridging the gap between fundamental medical research and commercial application, Technology Transfer supports both academic researchers and companies by funding applied research and development projects to a stage where they are attractive to a follow-on funder.
At this workshop you will hear about R&D projects that have already been funded by the Wellcome Trust and, more importantly, how you can access translational funding to support your research.
